David Ebsworth

David Ebsworth is non-executive chairman at Verona Pharma Plc. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. He is also an advisor to a variety of CEOs at public and private organisations.[1]

David Ebsworth
Born1954 (age 68–69)
NationalityBritish
OccupationNon-Executive Chairman
Years active1980-
Known forChairman, Pharmaceutical industry

Education

Ebsworth was educated in Germany, Singapore and England at the Duke of Yorks Royal Military School He gained his BSc in chemistry and German in 1976 and his Ph.D. in industrial relations in 1980 from the University of Surrey.[2] Ebsworth received an honorary doctorate from the University of New Haven in 2000.[3]

In 2001, he was awarded the ‘Global Citizen of the Year’ award from the Seton Hall University in New Jersey.[4]

Career

Ebsworth began his career at Pfizer in Germany. In 1983, he moved to Bayer AG, where he ultimately served as the president of North American business and the global head of pharmaceuticals.[5] He was with the company for more than 19 years before he resigned in 2002.[6]

After working at Bayer, Ebsworth was named the chief executive officer of Oxford Glycosciences, a biotech company listed on the London Stock Exchange and Nasdaq. Following the company's sale to Celltech in 2003, he became chairman of a number of organisations, such as Wilex AG and A&D Pharma Holdings NV,[7] as well as joining the board at SkyePharma PLC and other companies.[8]

Ebsworth was the CEO of Vifor Pharma for 5 years from 2009, and also the CEO of Galencia Group from 2011.[9] Notably, during his tenure as the CEO of Galenica Group, the company's value increased from CHF 2.4 billion to CHF 5.6 billion, with the company receiving two FDA approvals and one EMA approval.[10]

Ebsworth is currently an advisor to the CEO of Vifor Pharma and Galencia Santé, which now has a market cap of just under $10bn.[11]

In 2013, he set up the David Ebsworth Scholarship, which was worth £3,000 per year for four years, to help students who wanted to study German at the University of Surrey. Here, he has also founded the David Ebsworth Prize for Best Performance in the Professional Training Year and the David Ebsworth Student Opportunities Fund.[12]

Non-Executive Positions

Ebsworth is non-executive chairman of the board of directors at Verona Pharma, the drug development company focused on respiratory disease treatment.[13]

He has served on a number of boards across the pharma, biotech and healthcare sectors, in the UK, Germany, the US, Austria, Italy, Israel, Netherlands, and Japan. He has also advised venture capital and private equity companies.[14]

References
  1. "Stocks". Bloomberg News.
  2. "Stocks". Bloomberg News.
  3. "Dr. David Ebsworth Assumes Worldwide Management Responsibility for The Pharmaceutical Business". Archived from the original on 2016-06-24.
  4. "Stocks". Bloomberg News.
  5. "Stocks". Bloomberg News.
  6. Kapner, Suzanne (9 January 2002). "In Upheaval within Bayer, Chief Resigns at Drug Unit". The New York Times.
  7. "A&D Pharma HLDGS N.V | Statement re A&D PHARMA TO APPOINT NEW MANA... | InvestEgate".
  8. "SkyePharma Makes Non-Executive Board Appointment; David Ebsworth to Join Board of Directors". Archived from the original on 2016-06-24.
  9. "Verona Pharma - Board". Archived from the original on 2016-11-06. Retrieved 2016-05-25.
  10. "Galenica Prepares to Split in Two as CEO Ebsworth Steps Down". Bloomberg.com. 12 August 2014.
  11. "Verona Pharma - Board". Archived from the original on 2016-11-06. Retrieved 2016-05-25.
  12. "David Ebsworth Scholarship for 2013 - University of Surrey - Guildford". www.surrey.ac.uk. Archived from the original on 2013-05-08.
  13. "Dr David Ebsworth Appointed as Non-Executive Chairman - RNS - London Stock Exchange". Archived from the original on 2016-06-24. Retrieved 2016-05-25.
  14. "Dr David Ebsworth Appointed as Non-Executive Chairman - RNS - London Stock Exchange". Archived from the original on 2016-06-24. Retrieved 2016-05-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.